Alliance for Pandemic Preparedness

September 8, 2020

Convalescent Plasma in the Management of Moderate COVID-19 in India An Open-Label Parallel-Arm Phase II Multicentre Randomized Controlled Trial (PLACID Trial)

Category:

Topic:

  • [Pre-print, not peer-reviewed] COVID-19 convalescent plasma infusion was not associated with a reduction in mortality or progression to severe COVID-19 at 28 days post-enrollment (aOR=1.1, 95% CI: 0.7, 1.8) in a randomized trial among persons with moderate COVID-19 in India (n=464). Death or progression to severe disease occurred in 18.7% of participants in the intervention arm and 17.9% in the control arm.
  • Participants in the intervention arm received two doses of 200 mL convalescent plasma that were transfused 24 hours apart. An analysis limited to participants who received infusions within three days of symptom onset also found no significant difference in the composite outcome between intervention and control groups (aOR=0.6, 95% CI 0.2, 1.2).

Agarwal et al. (Sept 8, 2020). Convalescent Plasma in the Management of Moderate COVID-19 in India An Open-Label Parallel-Arm Phase II Multicentre Randomized Controlled Trial (PLACID Trial). Pre-print downloaded Sep 8 from https://doi.org/10.1101/2020.09.03.20187252